TyK2抑制剂deucravacitinib治疗系统性红斑狼疮的研究进展  

Research progress about TyK2 inhibitor deucravacitinib for the treatment of systemic lupus erythematosus

作　　者：赵玥 钟雪[1] 杨照[3] ZHAO Yue;ZHONG Xue;YANG Zhao(Dept.of Pharmacy,Peking University People’s Hospital,Beijing 100044,China;School of Pharmaceutical Sciences,Peking University,Beijing 100191,China;Research Department,Beijing University First Hospital,Beijing 100034,China)

机构地区：[1]北京大学人民医院药学部,北京100044 [2]北京大学药学院,北京100191 [3]北京大学第一医院科研处,北京100034

出　　处：《中国药房》2023年第12期1529-1531,共3页China Pharmacy

基　　金：北京大学人民医院研究与发展基金资助项目(No.RDJP2022-37)。

摘　　要：deucravacitinib是一种选择性酪氨酸激酶2抑制剂,对于各种免疫系统疾病均显示出一定的治疗潜力,其用于系统性红斑狼疮(SLE)目前还处在临床试验阶段。deucravacitinib口服给药易吸收,并可在24 h内引起药效学效应。与安慰剂比较,治疗第32周时,deucravacitinib组患者符合SLE反应指数4的比例更高,且在英国狼疮评估小组综合狼疮评估、皮肤红斑狼疮疾病面积和严重程度指数50、狼疮低疾病活动状态和活动、肿胀及压痛关节计数方面的反应率也更高。安全性方面,deucravacitinib组皮疹、痤疮等不良事件发生率较高,但仍需进一步观察。目前,已有更多研究正在对deucravacitinib治疗SLE的有效性和安全性进行评估,期待更多数据验证deucravacitinib的治疗潜力。Deucravacitinib is a selective tyrosine kinase 2 inhibitor.It has shown certain therapeutic potential for various immune system diseases,and its use in systemic lupus erythematosus(SLE)is currently in the clinical trial stage.Deucavacitinib is easily absorbed by oral administration and can cause pharmacological effects within 24 hours.Compared with placebo,after 32 weeks of treatment,patients in the deucravacitinib group who meet the SLE response index 4 have a higher proportion,and a higher response rate in the British Isles Lupus Assessment Group’s comprehensive lupus assessment,cutaneous lupus erythematosus disease area and severity index of 50,low disease activity status,and activity,swelling,and tenderness joint counts.In terms of safety,the incidence of adverse events such as rash and acne is higher in the deucravacitinib group than placebo group,but further observation was still needed.At present,more studies are evaluating the cost-effectiveness and safety of deucravatinib in the treatment of SLE,with the expectation of more data validation of deucravatinib’s therapeutic potential.

关 键 词：deucravacitinib 酪氨酸激酶抑制剂 系统性红斑狼疮 

分 类 号：R969[医药卫生—药理学] R967[医药卫生—药学]